J.P. Morgan Securities LLC Form 8.1a - Pfizer Inc (6868G)
24 November 2015 - 4:58AM
UK Regulatory
TIDMPFZ
RNS Number : 6868G
J.P. Morgan Securities LLC
23 November 2015
Ap9
APPENDIX 3 DISCLOSURE FORMS
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER
PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH
THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing J.P. Morgan Securities
(Note 1) LLC - PCS
======================= ======================
Company dealt in Pfizer Inc.
======================= ======================
Class of relevant Common Stock
security to which
the dealings being
disclosed relate
(Note 2)
======================= ======================
Date of dealing 20 November 2015
======================= ======================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
============================ ================== ===================
Number (%) Number (%)
============================ =========== ===== =========== ======
(1) Relevant securities 346,349 0.01
============================ ================== ===================
(2) Derivatives (other
than options)
============================ ================== ===================
(3) Options and agreements
to purchase/sell
============================ ================== ===================
Total 346,349 0.01
============================ ================== ===================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant Long Short
security:
============================= ==================== =====================
Number (%) Number (%)
============================= =========== ===== =========== ======
(1) Relevant securities
============================= ==================== =====================
(2) Derivatives (other
than options)
============================= ==================== =====================
(3) Options and agreements
to purchase/sell
============================= ==================== =====================
Total
============================= ==================== =====================
Ap10
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per
securities unit (Note
5)
============== ========================= ================
Sales 18 32.3200
2 32.4501
============== ========================= ================
(b) Derivatives transactions (other than options transactions)
Product Nature of Number of relevant Price
name, transaction securities per unit
e.g. CFD (Note 6) (Note 7) (Note
5)
========== ============= =================== ==========
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number Exercise Type, Expiry Option
name, selling, of securities price e.g. date money
e.g. purchasing, to which American, paid/received
call varying the option European per unit
option etc. relates etc. (Note
(Note 5)
7)
======== ============= =============== ========= =========== ====== ===============
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call per unit (Note
option 5)
============== =========================== ====================
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of Details Price per
transaction unit
(Note 8) (if applicable)
(Note 5)
============= ============== =====================
Ap11
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced. If none, this
should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 23 November 2015
========================= ===================
Contact name Tung T Le
========================= ===================
Telephone number 0207 742 7272
========================= ===================
Name of offeree/offeror Allergan plc
with which acting
in concert
========================= ===================
Specify category Adviser to Allergan
and nature of acting plc
in concert status
========================= ===================
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEEAXFDASKSFFF
(END) Dow Jones Newswires
November 23, 2015 12:58 ET (17:58 GMT)
Pfizer (LSE:PFZ)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (LSE:PFZ)
Historical Stock Chart
From May 2023 to May 2024
